



Session V: New Working Group Discussion Placebo Arm Database

Co-Chairs: Manal F. Abdelmalek, MD, MPH (Mayo Clinic)

Michael Cooreman, MD (Chief Medical Officer, Inventiva)

FDA: Frank Anania, MD

Liver Forum: Veronica Miller, PhD

Director, Forum for Collaborative Research



Mission of Placebo Arm Database

- Open dialog b/w all stakeholders and FDA/EMA
- Facilitate planning /powering of future trials
- Define natural history and/or placebo-response rates
- Decrease number of patients randomized to placebo vs active drug
- Develop better tools to stratify patient populations, assess treatment benefits and/or clinically meaningful outcomes
- Reduce time, size and cost of phase 3 trials through optimization




Liver Forum Placebo Arm DB Project

- Integrated patient-level DB from completed phase 2/3 NASH studies
- Natural history cohort representing patients eligible for RCT's
- Natural history across the spectrum of NASH stages in screened / enrolled in clinical trials
- Identify predictors of "placebo response" vs. disease progression
- Reduce placebo-arm burden in future phase 3 (phase 4) trials
- Increase specificity of patient selection
- Collaborative database serving the Liver Forum community, sponsors and regulators




Silos of Data





Integrated Construct—Placebo Arm DB





Highest Level of Security

Data will be housed in a secure research data and compute (SRDC) platform developed at Berkeley for researchers working with highly sensitive (P4 level) data.

PROTECTION LEVEL 4

- Protected Health Information (PHI) / patient records
- Research information classified as Protection Level 4
 (P4) by an IRB or otherwise required to be stored or processed in a high-security environment.
- Sensitive Identifiable Human Subject Research data including certain types of individually identifiable genetic information



- Direct access for regulatory agencies
- LF community (PDB WG) -- Propose analysis to benefit field



Framework for Arm DB Project



PDB Working Group

LF members experts from all stakeholder groups

PDB Oversight/Advisory Committee

Key expert representative from each stakeholder group:

- Academic, industry, regulatory, patient
- Guide/advise overall process
- Review analysis proposals
- Guide publication policy and process





Discussion

Thoughts...



Questions...



or Ideas...

